Israel Active

Tel Aviv University researchers have found that hyperbaric oxygen therapy (HBOT) is more effective than medication in reducing fibromyalgia pain caused by a traumatic head injury. 40% of the HBOT group were cured of fibromyalgia, compared to none receiving standard medication.

Doctors at the Galilee Medical Center in Nahariya implanted a cardiac pacemaker in Rachel Kafri who was born in Tel Aviv under the British Mandate 102 years ago. Rachel said. “I have been through so much in my life, but I am probably not ready to say goodbye to the world yet.”

On a flight from Tel Aviv to Chicago? - of course there is! A pediatric doctor from Jerusalem’s Hadassah hospital, and a United Hatzalah EMT, treated a 60-year-old man who fainted and fell over. Then they were called to stabilize a woman suffering from dehydration. All in a day’s work!

Hebrew University of Jerusalem Professor Haitham Amal has received a $400k grant from the Philadelphia Eagles Autism Foundation to develop treatments based on his nitric oxide research for autism spectrum disorder (ASD). Amal is the first researcher outside the US to be awarded the grant.

Jerusalem Mayor Moshe Lion has announced that the German company BioNTech intends to open a factory in Jerusalem where mRNA vaccines will be developed and produced. BioNTech partnered Pfizer in developing its mRNA-based Covid-19 vaccine.

The implant activation device, Active+ from Israel’s Nova Plasma gives dental implants a 30-sec deep-cleaning cold plasma bath immediately before they go into the patient’s mouth. Clinical results show a 50% improvement in integration and healing time.

Israel’s GrayMatters Health (see previously) has received US FDA clearance to market its Prism system, for post-traumatic stress disorder (PTSD). The patient wears Prism’s cap fitted with special electrodes. Software plus an audio-visual interface then helps calm emotions.

A unique, artificial intelligence-based system is helping paramedics in Israel save lives by transcribing poor-quality emergency phone calls to save precious time. The technology was developed by Israel’s AudioCodes (see previously) and is now installed at MDA’s 101 dispatch center.  

Israel’s BioBeat (see previously) has just completed a study of its wearable chest monitor in use on 521 patients. It reported a 77% success rate for detecting those at high risk of deterioration. This compared with 20% monitored using current alternative methods.

An international study let by Hebrew University researchers has discovered that pancreatic cancer spreads (metastasis) due to reduced levels of the RNA controlling protein RBFOX2. The finding provides a new target for pancreatic cancer treatments.